Related Experiment Video
Updated: Jan 10, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Immunomodulatory interventions in type 1 diabetes: a systematic review and meta-analysis revealing paradoxical
Shankar Biswas1, Bhavya Dhir2, Susmitha Talasila3
1Ivano-Frankivsk National Medical University, Ivano-Frankivsk, 76000, Ukraine. Sb740927@gmail.com.
Background:
Immunomodulatory therapies aim to preserve beta-cell function in type 1diabetes (T1D), yet their clinical translation remains inconsistent. Weconducted a systematic review and meta-analysis to quantify treatment effectson beta-cell preservation, glycemic control, and insulin requirements whileexamining time-dependent efficacy and safety profiles.
Methods:
We searched PubMed, Embase, and Cochrane CENTRAL for randomizedcontrolled trials evaluating immunomodulatory interventions (teplizumab,otelixizumab, low-dose IL-2) in T1D patients. Primary outcomes includedC-peptide area under curve, HbA1c, and insulin requirements analyzed asstandardized mean differences (SMD) using random-effects models.Meta-regression examined time-dependent treatment attenuation.
Results:
Nineteen studies (n = 1,852) were analyzed. Immunotherapy significantlypreserved C-peptide (SMD = 0.221, 95%CI: 0.069-0.373, p = 0.007) without improvingHbA1c (SMD = 0.033, 95%CI: -0.070-0.136, p = 0.488), demonstratingbiomarker-clinical outcome disconnect. Paradoxically, low-dose IL-2 producedmassive regulatory T-cell expansion (SMD = 2.23, p = 0.003) and improved HbA1c(SMD = -0.514, p = 0.025) without preserving C-peptide (SMD = 0.020, p = 0.967),suggesting non-immunological metabolic pathways. Insulin requirements showedmodest reduction in sensitivity analysis (SMD = -0.453, p = 0.021) with significanttime-dependent attenuation (R² = 49.06%, p = 0.009), indicating benefits fadeprogressively. WBCs Clearance agents demonstrated 3.2-fold higher seriousadverse event rates than Treg Enhancement agents (34.5% vs 10.8%), with all five reported deaths occurring with WBCs Clearance.
Conclusion:
Immunomodulation provides modest, temporary beta-cell preservationwithout consistent glycemic improvement. The C-peptide-HbA1c disconnect likelyreflects intensive insulin management masking treatment benefits. IL-2'sparadoxical HbA1c improvement without beta-cell preservation warrants mechanistic investigation. Time-dependent benefit attenuation suggests maintenance therapy may be necessary. Safety profiles favor Treg Enhancementover WBCs Clearance approaches. Future trials should employ continuous glucosemonitoring endpoints, longer follow-up, and combination strategies to optimizedisease-modifying therapy development.
Clinical Trial Number:
Not applicable.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

